Weight loss drugs are changing the economic picture from many angles. In addition to reshaping the healthcare, retail, and leisure industries, employers—including Bank of America—are now offering access to the medication as part of their healthcare benefits.
In fact, the impact of GLP-1s has become so huge that it is influencing the forecast for the entire Danish economy, which is home to pharmaceutical giant Novo Nordisk: the company behind Ozempic and Wegovy.
In a special report, the Danmarks Nationalbank (Denmark’s central bank), noted the country’s pharmaceutical industry saw “extraordinary” growth in the first half of 2026, with an increasing share of production taking place abroad under Danish ownership.
The report, released today, adds: “The growth is mainly due to Novo’s sales and production in the U.S. market at the beginning of this year. This reflects Novo’s agreement with the U.S. administration, which, from the turn of the year, has, among other things, provided access to a larger patient base through public health insurance schemes.”
-copy-29e15046.jpeg?w=600)
